Lung Cancer, Microwave Ablation
Conditions
Keywords
microwave ablation, lung cancer, ground glass nodules
Brief summary
GGO was commonly observed recently.Radiofrequency ablation has been widely applied in the treatment of patients with GGO. No study had explored the microwave ablation in the treatment of GGO.
Detailed description
GGO was common with the development of image. Treatments of GGO include radical surgery and irradiation. For patients who were poor candidate of surgery, image guided thermal ablation could be an alternative.Radiofrequency ablation has been widely applied in the treatment of eary-stage non small cell lung cancer and those patients with GGO. However, up to date, no study had explored the microwave ablation in the treatment of GGO.
Interventions
OTHERMicrowave ablaton
Patients with pathology verified GGO were treated with MWA.
Sponsors
Shandong Provincial Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
All patient with GGO were treated with microwave ablation
Intervention model description
All patient with GGO were treated with microwave ablation
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient has a histologically verified AIS or MIA. 2. The tumors small enough to treat (usually ≤3 cm), and without chest pleura invasion. 3. Solid cements in the GGO less than 50%. 4. No other sites of disease observed. 5. Patient is not a candidate for surgical removal of the cancer, or refused surgery. 6. Patient is not a candidate for radiation therapy, or refused radiation therapy. 7. Patient has \> 6 month life expectancy. 8. Eastern Cooperative Oncology Group performance status of 0 to 2. 9. No prior anticancer treatments including surgery, radiation,chemotherapy or local treatments. 10. Sufficient organ functions. 11. Written informed consent.
Exclusion criteria
1. Active bacterial or fungous infection. 2. Simultaneous or metachronous (within the past 5 years) double cancers. 3. Women during pregnancy or breast-feeding. 4. Interstitial pneumonitis, pulmonary fibrosis, or severe pulmonary emphysema. 5. Uncontrollable diabetes mellitus. History of severe heart disease, heart failure, myocardial infarction within the past 6 months or attack of angina pectoris within the past 6 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The survival of patients with GGO treated with MWA | From the date of randomization until the date of the date of death from any cause, assessed up to 60 months | The overall survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The disease free survival of patients with GGO treated with MWA | From date of randomization until the date of first documented progression, assessed up to 60 months | The disease free survival |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | 1 year | The safety |
Countries
China
Contacts
Primary ContactXin Ye
Backup ContactZhi g Wei
Outcome results
None listed